The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment

Table 4 Incidence rates and relative risks of abdominal or pelvic surgery (as-treated analysis)

Variable	Events	Person years	I.R.¹	95% Confidence interval		Rate ratio¹	95% Confidence Interval
				Low	High		Low	High
Tegaserod Use
Current	43	542	0.08	0.06	0.11	0.68	0.48	0.95
Recent	25	177	0.14	0.09	0.21	1.17	0.76	1.80
Past	28	393	0.07	0.05	0.10	0.59	0.39	0.89
Non-Use	132	1,090	0.12	0.10	0.14	1.00
Gender
Female	207	1,963	0.11	0.09	0.12	1.00
Male	21	237	0.09	0.05	0.14	0.85	0.54	1.33
Age
0 - 29	25	289	0.09	0.06	0.13	1.00
30 - 49	144	1,110	0.13	0.11	0.15	1.47	0.96	2.26
50 +	59	802	0.07	0.06	0.09	0.85	0.53	1.36
Surgery Risk Factors
Cholelithiasis (574)	19	43	0.45	0.27	0.69	3.25	2.00	5.28
Colonoscopy (45355–45387)	54	496	0.11	0.08	0.14	0.95	0.69	1.31
Irritable Bowel Syndrome (564.1)	89	910	0.10	0.08	0.12	0.88	0.67	1.15
Gastritis and Duodenitis (535)	47	312	0.15	0.11	0.20	1.37	0.98	1.91
Diagnostic Procedures²	80	437	0.18	0.15	0.23	1.92	1.45	2.55

¹ Adjusted for gender, age, cholelithiasis, colonoscopy, irritable bowel syndrome, gastritis and duodenitis, and diagnostic procedures.
² Composite variable consisting of MRI abdomen, other diagnostic procedures involving the abdomen or pelvis, radiologic small bowel examination, rectum or anus diagnostic procedures, urinary tract diagnostic procedures, radiographic visualization of the gallbladder, and abdominal radiologic examination.

ISSN: 1471-230X